

Resource Summary Report

Generated by [RRID](#) on Aug 29, 2026

IOMM-Lee

RRID:CVCL_5779

Type: Cell Line

Proper Citation

RRID:CVCL_5779

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5779

Proper Citation: RRID:CVCL_5779

Description: Cell line IOMM-Lee is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Intracranial meningioma

Defining Citation: [PMID:2234331](#), [PMID:16554968](#), [PMID:18261772](#), [PMID:25984343](#), [PMID:28552950](#), [PMID:31068700](#), [PMID:34850056](#)

Comments: Population: Chinese., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: IOMM-Lee

Synonyms: IOMM-LEE, Iomm-Lee, IOMM Lee, IOMMLEE, IntraOsseous Malignant Meningioma-Lee

Cross References: BTO:BTO_0004464, ATCC:CRL-3370, BioSample:SAMN10988414, cancercellines:CVCL_5779, Cell_Model_Passport:SIDM01733, Cosmic:2516047, DepMap:ACH-000629, Pharmacodb:IOMMLee_661_2019, Wikidata:Q54897853

ID: CVCL_5779

Record Creation Time: 20220427T220637+0000

Record Last Update: 20260815T234325+0000

Ratings and Alerts

No rating or validation information has been found for IOMM-Lee.

No alerts have been found for IOMM-Lee.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang L, et al. (2026) KMT2C Loss Promotes NF2-Wildtype Meningioma Progression and Ferroptosis Sensitivity via Epigenetic Repression of Hippo Signaling. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(20), e22756.

Yang J, et al. (2026) DNA-Loaded Nanoparticles Reprogram the Tumor Immune Microenvironment to Treat Brain Tumors. *Small science*, 6(1), e202500475.

Maeoka R, et al. (2025) Immunotherapy using allogenic NK cells downregulates mitochondrial-related genes and inhibits the OXPHOS system of malignant meningioma. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 187, 118099.

Liu X, et al. (2023) Tumor-selective Blockade of CD47 Signaling with CD47 Antibody for Enhanced Anti-tumor Activity in Malignant Meningioma. *Current neuropharmacology*, 21(10), 2159.

Kawamura Y, et al. (2022) Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 155, 113843.

Jia Z, et al. (2022) A novel NF2 splicing mutant causes neurofibromatosis type 2 via liquid-liquid phase separation with large tumor suppressor and Hippo pathway. *iScience*, 25(11), 105275.

Zhang Q, et al. (2020) MicroRNA-221/222 Inhibits the Radiation-Induced Invasiveness and Promotes the Radiosensitivity of Malignant Meningioma Cells. *Frontiers in oncology*, 10, 1441.

Xie Q, et al. (2018) N6-methyladenine DNA Modification in Glioblastoma. *Cell*, 175(5), 1228.